The TGF-β/Smad2/3 pathway acts as a significant factor contributing to renal fibrosis; thus, targeting the TGF-β/Smad2/3 pathway could suppress profibrotic response in DN. This evidence concerns the gene SMAD2 and liver dysplastic nodule.